Gabapentin Tablet, Film Coated
Product Images NDC 70518-2356

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 70518-2356). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Mm2 (Gabapentin 600mg 70518 2356 01)

Gabapentin 600 mg film-coated tablets packaging label showing a quantity of 90 tablets. The label includes the product name, strength, dosage form, and repackager RemedyRepack Inc. It displays NDC 70518-2356-01, manufacturer information (Aurobindo, India), and general storage directions. The label also states RX ONLY and includes a QR code.*

FDA Label Image

Gabapentin 600mg 70518 2356 02

Gabapentin 600 mg film-coated tablets label showing product name, strength, dosage form, and quantity of 120 tablets. The label includes manufacturer information (Aurobindo, India) and repackager RemedyRepack Inc. with storage instructions and a QR code. This is an oral human prescription drug for Rx only.*

FDA Label Image

Gabapentin 600mg 70518 2356 03

Gabapentin 600 mg film-coated tablets label showing a quantity of 180 tablets. The label includes the NDC number 70518-2356-03, manufacturer as Aurobindo, India, and repackager RemedyRepack Inc., Indiana, PA. It has storage instructions and a QR code.*

FDA Label Image

Remedy_label (Remedy Label)

Gabapentin 600 mg film-coated tablets packaging label showing a quantity of 30 tablets. The label displays the drug name, strength, dosage form, and repackager RemedyRepack Inc. The label includes the NDC number 70518-2356-00, manufacturing location in India, and storage instructions with a QR code on the upper right.*

FDA Label Image

Creatinine Clearance (Gabapentin Fig1)

A formula illustrating a clinical clearance calculation for creatinine, specifying variables such as age, weight, serum creatinine, and a factor adjustment for female patients.*

FDA Label Image

Figure 1. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 1 (Gabapentin Fig2)

A line graph titled 'Weekly Mean Pain Scores (Observed Cases in ITT Population): Study 1' comparing mean pain scores over 8 weeks between placebo and Gabapentin 3600 mg/day. The x-axis represents weeks, including baseline, while the y-axis shows mean pain scores ranging from 0 to 10. The graph indicates a 4-week dose titration period followed by a 4-week fixed dose period.*

FDA Label Image

Figure 2. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 2 (Gabapentin Fig3)

A line graph titled 'Figure 2. Weekly Mean Pain Scores (Observed Cases in ITT Population): Study 2' showing mean pain scores from baseline to week 7. The x-axis represents weeks and the y-axis represents mean pain scores from 0 to 10. Data lines compare placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day over a 3-week dose titration period followed by a 4-week fixed dose period.*

FDA Label Image

Figure 3. Proportion Of Responders (patients With ≥50% Reduction In Pain Score) At Endpoint: Controlled Phn Studies (Gabapentin Fig4)

A bar graph titled 'Proportion of Responders (patients with ≥50% reduction in pain score) at Endpoint: Controlled PHN Studies' showing comparison between placebo (PBO) and gabapentin (GBP) doses in two studies. Study 1 compares PBO to GBP 3600 mg, and Study 2 compares PBO to GBP 1800 mg and GBP 2400 mg, with higher responder proportions in GBP groups indicated by percentages above bars.*

FDA Label Image

Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study: Adjunctive Therapy Studies In Patients ≥12 Years Of Age With Partial Seizures (Gabapentin Fig5)

A scatter plot figure titled 'Responder Rate in Patients Receiving Gabapentin Expressed as Difference from Placebo by Dose and Study' showing additive therapy studies in patients aged 12 years or older with partial seizures. The plot depicts difference (%) on the y-axis versus daily dose (mg) on the x-axis, with three separate studies represented by different symbols indicating responder rate differences at various gabapentin doses (600 mg, 900 mg, 1200 mg, 1800 mg).*

FDA Label Image

Chemical Structure (Gabapentin Str)

Chemical structure of Gabapentin, showing a cyclohexane ring with amino (CH2NH2) and carboxymethyl (CH2CO2H) functional groups attached.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.